BioSolution Acquires Additional Helixmith Shares Worth 3.4 Billion KRW
BioSolution announced on the 5th that it will additionally acquire 936,066 shares of its subsidiary Helixmith, which is engaged in medical and pharmaceutical research and development, for approximately 3.4 billion KRW.
After the stock acquisition, BioSolution's stake in Helixmith will be 16.8%. The scheduled date for the stock acquisition is April 25 of this year.
Hot Picks Today
"Over 20 Times More Than Overseas": 104.5 Milli...
- "Only the Top 1% Winning Big in Stocks Smile... '300 Million Won Splurges' or '1...
- Applied Just for Skin Soothing...Study Finds It Suppresses Antibiotic Resistance
- "If an Accident Happens, Teachers Go to Jail"... The Real Reason Behind Fewer Sc...
- "Please Launch It in Korea!" After All the Hype... This Coffee Finally Arrives i...
BioSolution stated that the purpose of this stock acquisition is to "maximize corporate value through additional share acquisition."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
